Betta Pharmaceutical announced that the company's application for clinical trials of injectable BPI-585771 intended to treat advanced solid tumors has been accepted by the State Drug Administration. The acceptance number is CXHL2601308.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.